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ABSTRACT 
The use of biologics targeted to the HER2 protein is the latest addition to the 
armamentarium used to fight advanced gastric or gastro-oesophageal junction 
carcinoma. The decision to treat with the biologic trastuzumab is completely dependent 
upon HER2 testing of tumour tissue. In 2017, the College of American Pathologists, 
American Society for Clinical Pathology and the American Society of Clinical Oncology 
jointly published guidelines for HER2 testing and clinical decision making in gastro-
oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular 
Pathology and Diagnostics Committee has issued the following document as a 
commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in 
NHS pathology departments within the UK. This guidance covers issues related to case 
selection, pre-analytical aspects, analysis and interpretation of such HER2 testing. 
 
KEY WORDS 
Adenocarcinoma, Stomach, Oesophagus, HER2, immunohistochemistry, in-situ 
hybridisation, guidance. 
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INTRODUCTION 
A ‘biologic’ is a recombinant monoclonal antibody directed against a specific antigen. 
The use of biologics is becoming increasingly commonplace in the management of both 
cancers and inflammatory diseases. A biologic (trastuzumab, also known as Herceptin) 
targeting the human epidermal growth factor receptor 2 (HER2) has been shown to 
improve outcomes in patients with advanced gastric or gastro-oesophageal junction 
(GOJ) adenocarcinoma.[1] Furthermore, a technology appraisal guidance (TA208) 
issued by the National Institute for Health and Care Excellence (NICE) in 2010, has 
supported the use of trastuzumab, in combination with cisplatin and capecitabine (or 5-
fluorouracil), in patients with HER2 positive metastatic adenocarcinoma of the stomach 
or GOJ, who have not received prior treatment for the metastatic disease.[2] 
The clinical use of trastuzumab is dependent on demonstration of either aberrant HER2 
expression (by immunohistochemistry, IHC) or HER2 gene amplification (by In-Situ 
Hybridisation, ISH) in the patient’s tumour. Guidance documents on HER2 testing of 
upper gastrointestinal tumours have been published.[3 4] Most recently, the College of 
American Pathologists (CAP), the American Society for Clinical Pathology and the 
American Society of Clinical Oncology jointly published a guidance document entitled 
“HER2 testing and clinical decision making in gastroesophageal adenocarcinoma”.[5] 
These guidelines (henceforth referred to as the ‘CAP-guidelines’ for brevity) included a 
list of recommendations. The following document - issued by the Association of Clinical 
Pathologists Molecular Pathology and Diagnostics Committee 
(http://www.pathologists.org.uk/page.aspx?id=130) - is a commentary, particularly of 
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these CAP-guidelines, and, in addition, provides guidance on HER2 testing of gastric 
and GOJ adenocarcinoma, in the context of the NHS in the United Kingdom. 
 
The guidance will focus on the technical aspects of HER2 testing together with its 
interpretation and reporting, rather than clinical decision making. As such, this 
document is structured to follow the specimen pathway of HER2 testing and uses a 
similar format to that of guidance previously issued by this Committee.[6] At each step 
of this pathway, any relevant and corresponding recommendation from the CAP-
guidelines will be discussed. 
 
CASE SELECTION FOR TESTING 
Appropriate case selection is essential for successful and cost-effective application of a 
test. The CAP-guidelines are introduced with a statement that gastro-oesophageal 
adenocarcinoma represents the 8th (oesophageal) and 5th (stomach) most common 
cancers worldwide, and then cite previous literature based on adenocarcinoma of the 
stomach or GOJ.[5] Similarly, the NICE TA208 document specifically states that 
trastuzumab be considered for metastatic adenocarcinoma of the stomach or GOJ.[2] It 
is noted that neither document[2 5] nor the original ToGA trial publication[1] precisely 
defines a GOJ tumour and its distinction from adenocarcinoma of the oesophagus. This 
may be a moot point in that oesophageal adenocarcinoma frequently arises on a 
background of Barrett’s metaplasia and is almost always located in the distal 
oesophagus, which would usually meet the definition of a Siewert type I GOJ tumour 
(i.e. with an epicentre which is no more than 5 cm proximal to the GOJ[7]).  The 
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Committee is not aware of UK multidisciplinary teams which exclude oesophageal 
adenocarcinoma patients from trastuzumab therapy purely based on the anatomical 
location of their tumours. However, for clarity, the following document and its 
recommendations pertain to oesophageal, GOJ and gastric adenocarcinomas as a 
whole. As such, all three tumour types will be collectively referred to by the term ‘gastro-
oesophageal adenocarcinoma’ hereafter.  
     
It remains controversial whether molecular testing of tumours, particularly in the setting 
of personalised medicine, is best performed as a reflex (i.e. on all cases) or whether 
such testing should be performed at request/on demand. In view of how trastuzumab is 
licensed for use in the UK (only for patients with metastatic disease) and in the setting 
of the NHS, HER2 testing of gastro-oesophageal adenocarcinoma is generally 
performed on demand.  Requests are almost exclusively made by a multidisciplinary 
team or an oncologist. This practice is in accordance with the CAP-guideline that “in 
patients with advanced GEA who are potential candidates for HER2-targeted therapy, 
the treating clinician should request HER2 testing on tumor tissue”.[5] However, there is 
an argument that reflex HER2 testing of gastro-oesophageal adenocarcinomas would 
prevent delays to the start of treatment with trastuzumab, and that resource saved and 
improved outcomes achieved by preventing these delays would compensate for the 
extra cost of reflex testing. Whether HER2 testing is performed as a reflex or on 
demand procedure should be decided at a local level following consideration of these 
health economic factors. 
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Neoplasm Type 
Both the NICE TA208 document[2] and the CAP-guidelines[5] specify that HER2 testing 
should only be performed on adenocarcinoma. The morphological distinction between 
high grade dysplasia and intramucosal adenocarcinoma can be particularly 
challenging.[8] The Committee is aware of the practice of treatment decisions based on 
the scoring of high grade dysplasia alone when adenocarcinoma cannot be confidently 
diagnosed in the tested tissue. However, the CAP-guidelines note that “false positivity” 
can be seen in areas of high grade dysplasia and recommend that these areas should 
not be scored (in the same way in-situ disease is not scored for HER2 expression in 
breast cancer).[5] In one study of 13 cases of paired gastric dysplasia and carcinoma, 
seven showed discordant HER2 protein expression between the dysplasia and 
carcinoma; four of these seven cases showed expression in the dysplasia but not the 
carcinoma.[9] Therefore and in order to prevent over-treatment, it is recommended that 
HER2 scoring is only performed on tumour foci which unequivocally demonstrate 
carcinoma.   
 
Another neoplasm type for which HER2 testing remains controversial is poorly 
differentiated carcinoma. The CAP-guidelines acknowledge that HER2 data on variants 
of adenocarcinoma (for example adenosquamous) are limited.[5] Based on the 
probability of cancer of the stomach and GOJ being of glandular origin, it is suggested 
that if a carcinoma shows only a focal glandular component or, after full work-up, shows 
no demonstrable line of differentiation, it is acceptable to test for HER2 expression and 
agree a treatment decision with the patient.   
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Specimen Type 
Primary tumour versus metastatic deposit 
In the case of metastasis or recurrence, it would be ideal to HER2 test the metastatic or 
recurrent tumour as tumours may evolve with time. However, a diagnosis of 
metastasis/recurrence is frequently made on clinical or radiological grounds without 
definitive tissue diagnosis. The CAP-guidelines, based on studies comparing primary 
tumour with lymph node metastases and primary tumour with both synchronous and 
metachronous liver metastases, recommend that HER2 testing can be performed on 
either primary or metastatic carcinoma.[5]  This recommendation is generally supported 
though a nuanced approach should be considered in the following scenario. It is known 
that chemotherapy and radiotherapy can exert selection pressures on a tumour.[10] 
Thus, if a patient had received neoadjuvant and/or adjuvant therapy prior to recurrence, 
it is recommended that HER2 testing is performed on tissue sampled after the therapy 
and, when such tissue is not available and where clinically reasonable, efforts are made 
to obtain tissue from the recurrence for the purposes of HER2 testing. 
 
Biopsy versus resection 
The CAP-guidelines recommend that HER2 expression can be tested on either biopsy 
or resection specimens as review of admittedly limited published literature suggests a 
"fair degree of concordance".[5] However, within NHS practice, it is recommended that, 
when the choice is available, HER2 testing is preferentially performed on resection 
tissue in order to obviate the effects of intratumoral heterogeneity. The confounding 
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effects of heterogeneity are acknowledged by the CAP guidelines which recommend 
that, if only biopsies are available for testing, a minimum of 5 biopsy fragments and 
optimally 6-8 should be obtained for biomarker testing.[5] While this is a worthy 
aspiration, it is unlikely that this will always be achieved in the NHS setting, and 
therefore this minimum number of biopsies should not be used to preclude a biopsy 
specimen from HER2 testing. Finally, this Committee endorses the CAP-guidelines 
proposal that cytology specimens (particularly cell blocks of fine needle aspiration 
specimens) are acceptable for HER2 testing if no other tissue is available.[5] 
 
PRE-ANALYTICAL ASPECTS 
Optimal pre-analytical preparation of tissue is crucial to achieving a high standard of 
subsequent molecular testing.[11] The CAP-guidelines evaluated published data on the 
effects of delayed tissue fixation (cold ischaemia) on both immunohistochemistry for 
HER2 expression and ISH for HER2 amplification. For optimal downstream analysis, it 
is recommended that biopsies or resection specimens are immersed in fixative within 
one hour of sampling/resection.[5]  Within an NHS setting, most (if not all) endoscopic 
biopsies will be fixed immediately after sampling. Achieving this target for upper GI 
surgical resections will be less likely especially if fresh tissue is required for other 
purposes such as research. Sampling of fresh tissue is usually undertaken in the 
Pathology department. Cold ischaemia may be exacerbated by delays in transport from 
surgical theatre to the Pathology department and, once the specimen has arrived, 
delays in sampling and formalin fixation. If there are likely to be delays in either 
transport or sampling, specimens should be refrigerated in order to reduce the rate of 
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cellular degradation. Finally, samples submitted fresh should be clearly documented as 
such and, if possible, the actual cold ischaemia time should be indicated in the final 
histopathology report.   
 
Different fixative types can potentially affect subsequent molecular testing[11] although 
this was not discussed in the CAP-guidelines.  It has been reported that, compared with 
10% neutral buffered formalin (NBF), fixation in 20% NBF or non-buffered formalin 
reduces intensity of HER2 immunostaining.[12] Therefore, only 10% NBF is 
recommended for gastro-oesophageal adenocarcinoma specimens (biopsies and 
resection specimens) which may potentially undergo HER2 testing. Where other 
fixatives are used or have been used on tissue which is then HER2 immunostained, 
caution should be exercised when interpreting this HER2 immunostaining. 
 
Both under-fixation (insufficient time in fixative) and over-fixation (excessive time in 
fixative) can affect IHC and ISH. When using 10% NBF, the CAP-guidelines 
recommend a fixation period of 6 – 72 hours. Most biopsies are unlikely to remain in 
fixative for more than 24 hours and  given the small size of the tissue fragments, under-
fixation is not likely to be a problem. For resection specimens, assuming there is an 
adequate volume of fixative, a minimum of 24 hours fixation is recommended. 
 
A previous study of breast carcinoma (in patient tissue specimens or as xenografts of a 
cell line) showed that, of three decalcifying treatments tested, only hydrochloric acid 
(and neither EDTA nor formic acid) had a deleterious effect on HER2 ISH.[13] By 
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contrast and as was noted in the CAP guidelines, the exact effects of decalcifying 
treatments on HER2 immunohistochemistry are unknown. Although it is rare, it is 
possible that for such HER2 testing may be requested on tissue which needs treatment 
with decalcifying agents (such as bony metastases). Given the studies demonstrating 
concordance between primary tumours and metastases, it is recommended that HER2 
immunohistochemistry is performed on earlier biopsy/resection material if this had been 
processed without decalcification. 
  
The CAP-guidelines did not directly address the effect of tissue block age on 
subsequent HER2 testing or whether pre-cut sections are suitable for such testing. 
However, with regards to the former and in the experience of Committee members, it is 
highly unusual for HER2 testing of oesophageal and gastric adenocarcinoma to be 
requested on tissue blocks of greater than 5 years of age.  Work on breast carcinoma 
has shown that HER2 protein antigenicity is reduced in pre-cut and stored tissue 
sections.[14] While there are no known published, equivalent data for gastro-
oesophageal adenocarcinoma, this document recommends that only freshly cut 
sections be used for HER2 IHC and ISH of gastro-oesophageal adenocarcinoma. 
  
With regards to cytological specimens, the CAP-guidelines acknowledge the potential 
effects of different fixatives (e.g. alcohol versus formalin fixation) on HER2 testing.[5] 
The guidelines therefore stress the need for proper evaluation of such testing on 
cytological specimens in individual laboratories before such testing is used to guide the 
management of clinical patients. This is endorsed, as with any other example of 
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immunohistochemistry applied to cytological samples in the context of personalised 
medicine.[15] 
 
ANALYTICAL ASPECTS 
Assay choice 
The CAP-guidelines recommend assessment of HER2 expression by IHC as the test of 
choice, with ISH used only when IHC yields a 2+ score. Further, the European 
Medicines Agency stipulates that trastuzumab “should only be used in patients with 
metastatic gastric cancer whose tumours have HER2 overexpression as defined by 
IHC2+ and a confirmatory SISH or FISH result, or by an IHC3+ result.”[16] This 
document further proposes that if there is any equivocation between a 1+ and 2+ score, 
the latter should be reported and ISH performed. There are published data showing that 
HER2 gene amplification may occur without expression of HER2 protein.[17]  However, 
because there is no documented benefit of treatment with trastuzumab in the absence 
of tumour HER2 protein expression, the above recommended sequence of testing 
remains justified.  
 
The CAP-guidelines do not recommend any specific antibody or specifically comment 
on immunohistochemical protocols (with regards to, for example, antigen retrieval) or 
staining platforms for HER2 testing.[5] However, the CAP-guidelines do recognise 
previous reports that the 4B5 antibody may produce stronger staining than other 
antibodies.[5] It is also worth noting that this antibody usually decorates physiological 
foveolar epithelium (often with a weaker membranous and stronger cytoplasmic and/or 
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nuclear pattern). Finally, it is recognised that several commercial HER2 antibodies are 
only available in pre-diluted preparations and that many are marketed with 
recommended protocols and/or are tied to specific staining platforms. 
 
There are various ISH methods (for example, FISH, CISH and D-DISH) available for the 
study of gastro-oesophageal adenocarcinoma. The CAP-guidelines recognise that 
brightfield ISH techniques may be advantageous over FISH because they can be 
performed on automated platforms, do not require fluorescence microscopy and permit 
easier identification of neoplastic nuclei.[5]  However, as with immunohistochemistry, no 
specific ISH method is considered as being superior for use in the NHS setting. HER2 
ISH can be performed with single probe (HER2 only) or dual probe (HER2 and 
centromere 17, CEP17) systems. This Committee recommends only the use of dual 
probe systems for ISH of gastro-oesophageal adenocarcinoma.   
  
This Committee endorses the CAP-guidelines that whichever assay chosen, it is 
appropriately validated and continuously monitored through participation in quality 
assurance schemes.[5]  It is questionable whether technical details (e.g. which antibody 
and which ISH technique were used) in a HER2 report are of interest and use to the 
patient’s clinical team. However, it is still recommended that such details are retained in 
the report to facilitate quality and process-related audits performed by the laboratory 
itself and/or external assessors.  
 
Assay validation  
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There is variation in the proposed numbers of cases which should be validated by a 
laboratory before it offers clinical HER2 testing. Recommendation 2.1 of the CAP-
guidelines refers to the CAP laboratory accreditation program for HER2 validation of 
breast carcinomas which proposes validation using 20 positive and 20 negative 
specimens for an FDA-approved test and 40 positive and 40 negative cases for a 
laboratory developed test.  By contrast, the updated UK recommendations for HER2 
assessment in breast cancer recommends validation by dual HER2 
immunohistochemistry and ISH of a minimum number of 100 cases of breast 
carcinoma.[18] This Committee is not aware of any published data defining and 
justifying the minimum number of cases needed to validate HER2 testing of gastro-
oesophageal adenocarcinoma. The most clinically significant events are under-calling of 
2+ scores as 1+ (leading to potential under-treatment) and over-calling of 2+ scores as 
3+ (leading to potential over-treatment). While the following numbers are arbitrary, it is 
sensible to include the entire range of HER2 immunoscores as part of the validation 
exercise. Thus, it is recommended that such validation be performed on gastro-
oesophageal adenocarcinoma tissue with a minimum of 20 reference cases in each 
category of 0/1+, 2+ and 3+. All the HER2 testing techniques (IHC and/or ISH) that the 
laboratory plans to offer clinically should be applied to these reference cases. 
 
Test failure 
A ‘false negative’ immunohistochemical score (i.e. a HER2 expressing carcinoma which 
does not immunostain for the protein) may occur due to pre-analytical and analytical 
failure. Regarding the former, the 4B5 antibody is useful because positive staining of 
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foveolar epithelium and intestinal metaplasia serves as an internal positive control. 
Technical failures can be reduced by using a positive control with each batch of HER2 
immunostaining. Ideally, the positive control tissue should be mounted on the same 
slide as the clinical case tissue (see below for types of control tissue). Whether it is 
mounted on the slide or a separate slide, assessing the positive control tissue 
(particularly the 0 and 2+ samples) before the patient tissue, is crucial to exclude the 
possibility of over-staining and to therefore prevent a ‘false positive’ 
immunohistochemical score.   
 
For HER2 ISH and as had been highlighted in the CAP-guidelines,[5] normal signals 
(i.e. up to 2 copies per cell of discrete HER2 and CEP17 signals) should be detected in 
non-neoplastic cells (such as stromal cells) and failure to detect probe signals in these 
cells is an indicator of poor quality hybridisation. 
 
POST-ANALYTICAL ASPECTS 
Reporting and interpretation 
The Rüschoff/Hofmann grading system for HER2 IHC and ISH[4] is universally used as 
the scoring method for gastro-oesophageal adenocarcinoma. Its use is recommended 
by the CAP-guidelines and further endorsed by this Committee. The Figure presents 
examples of 0, 1+, 2+ and 3+ HER2 scores of the Rüschoff/Hofmann grading system for 
gastro-oesophageal adenocarcinoma.[4] It is reiterated that the 4B5 antibody will 
decorate physiological foveolar epithelium and, therefore, this should not be mistakenly 
scored as positive expression. In addition, intestinal metaplasia (IM) can overexpress 
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HER2[19] which, in cases where the IM component is small and adjacent to or 
embedded within the carcinoma, can lead to interpretative confusion. It is worth 
repeating that only membranous staining is scored whilst both cytoplasmic and nuclear 
expression are ignored. Finally, for 2+ and 3+ scores, this membranous staining must 
be complete, basolateral or lateral whereas luminal staining by itself is considered a 
negative finding. In clinical practice, the following rule-of-thumb has emerged to aid 
grading of HER2 immunohistochemistry for gastro-oesophageal adenocarcinoma: if 
membranous staining can be clearly seen at x4 objective, the score is 3+; if 
membranous staining can only be clearly seen at x10 objective or higher, the score is 
2+; if membranous staining can only be clearly seen at x20 objective or higher, the 
score is 1+. 
  
By the Rüschoff/Hofmann method, the highest HER2 score of a carcinoma in a surgical 
resection specimen must be from a focus representing 10% or more of the carcinoma 
area, whereas for biopsies, the highest score is taken from a focus comprising 5 or 
more carcinoma cells. It is presumed that the rule for biopsies was formulated to 
acknowledge limited sampling of the whole tumour. In view of this, it is recommended 
that these rules be identically applied when metastatic tumour tissue is assessed. For 
example, the 10% rule would be used for a completely resected peritoneal metastasis 
whereas the 5+ cell rule would be used for a core biopsy of a liver metastasis.  
 
The CAP-guidelines recommend the use of 4 micron thick paraffin sections for ISH 
studies.[5] Their recommendation 2.6 is that areas of invasive adenocarcinoma are 
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identified and those areas with strongest intensity HER2 expression be marked to assist 
any subsequently required ISH scoring.[5] The CAP-guidelines recommend scoring of 
at least 20 non-overlapping tumour cell nuclei to calculate a ratio of HER2 to CEP17 
signals, and define HER2 amplification as a ratio of ≥2 and absence of amplification as 
a ratio of <2.[5] In the latter scenario but where there is an average CEP17 signal count 
of 3 or more, the CAP-guidelines (presumably in recognition of the 2013 American 
Society of Clinical Oncology / CAP guidelines on HER2 testing of breast carcinoma[20])  
then define amplification based on average numbers of HER2 signals alone: positive if 
more than 6 signals; negative is less than 4 signals , and equivocal if between 4 and 6 
signals.  
 
This definition of HER2 amplification when the HER2 to CEP17 ratio is <2 remains 
controversial. However, to maintain alignment of guidelines internationally and in 
keeping with the recently updated UK breast cancer HER2 guidelines,[18] this 
Committee defines HER2 amplification in gastro-oesophageal adenocarcinoma as a 
HER2 to CEP17 ratio of ≥2 and/or an average HER2 signal count of 6 or more. If this 
ratio is <2, an average HER2 signal count of <4 indicates non-amplification and a count 
between 4 and 6 indicates an equivocal result. For equivocal cases, the following may 
be then be performed, as recommended by the CAP-guidelines[5]: consultation 
between scorer and pathologist regarding selection of malignant cells or tumour areas 
for scoring; selecting a different tumour block for HER2 testing; and/or using other 
genomic analyses or an alternative method to evaluate HER2 amplification (though see 
below regarding availability of molecular techniques in the NHS setting). 
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Report layout 
As with pathology reporting of cancer resection specimens, use of templates in 
molecular pathology helps ensure neither important clinical nor technical information is 
omitted from final reports. Recommendation 2.5 of the CAP-guidelines is that HER2 test 
results should be reported using the College of American Pathologists template for 
HER2 biomarker testing.[5] Similar template reporting, with at least the data points 
presented in Table 1, is recommended. 
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TABLE 1 
 
HER2 testing may be performed on primary or metastatic carcinoma tissue, and 
on biopsy or resection specimen tissue, or on a cytology specimen if no other 
tissue sample is available. 
 
It is acceptable to HER2 test a carcinoma which shows no demonstrable line of 
differentiation or shows only a focal glandular component. 
 
10% neutral buffered formalin should be used to fix gastro-oesophageal 
adenocarcinoma specimens (biopsies and resection specimens) which may 
potentially undergo HER2 testing. 
 
Freshly cut tissue sections should be used for HER2 IHC and ISH. 
 
No specific antibody clone or ISH technique can be recommended but the 
assay(s) chosen should be appropriately validated and continuously monitored 
through participation in external quality assurance schemes. 
 
Validation should be completed with a minimum of 20 cases of 0/1+ scores, 20 
cases of 2+ score and 20 cases of 3+ score, using all the HER2 techniques 
(IHC and/or ISH) that the laboratory plans to offer clinically. 
 
A positive control should be run with each batch of HER2 IHC. 
 
The positive control used for HER2 IHC should include, as a minimum, 
examples of 0, 2+ and 3+ immunoscores. 
 
HER2 IHC and ISH should be scored using the Rüschoff/Hofmann method. 
 
If ISH yields a HER2/CEP17 ratio of  less than 2.0, HER2 amplification is then 
defined by the average number of HER2 signals: positive if more than 6 signals; 
negative is less than 4 signals, and equivocal if between 4 and 6 signals. . 
 
If only immunohistochemistry is required and is performed in house, >90% of 
cases should be reported within 5 days of receipt or collection of the tissue 
block. If both immunohistochemistry and ISH are required and are performed in-
house, then >90% of cases should be reported within 10 days of receipt or 
collection of the tissue block. 
 
If specimens are outsourced for HER2 testing, 90% of these specimens should 
be sent to the testing laboratories within 3 working days of tissue processing. 
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QUALITY CONTROL AND ASSURANCE 
The quality of HER2 testing is dependent on two major components: the technical 
quality of the assays, and the laboratory’s ability to correctly interpret the results of the 
assays. The two components are effectively independent of one another but are equally 
crucial to reaching a correct clinical outcome from HER2 testing. For example, even the 
best-trained and most experienced assessor cannot report clinically useful findings from 
a substandard HER2 immunostudy, and equally, incorrect interpretation of a high quality 
HER2 immunostudy can misdirect clinical management. Therefore, quality control 
programs must consider both components of HER2 testing and ideally be able to 
assess each component separately.      
 
Internal 
As with any molecular test for cancer patients,[21] internal controls should be run with 
each round of HER2 testing. The CAP-guidelines suggest that HER2 expressing breast 
carcinoma tissue may be initially used at positive controls but should be changed to 
actual gastro-oesophageal adenocarcinoma tissue when possible.[5] Also, gastric 
carcinoma cell lines showing HER2 expression can be used as positive controls if actual 
carcinoma specimens are not available.[5] This Committee endorses these 
recommendations and further extends them with the proposal that the controls should 
show, as a minimum, 0, 2+ and 3+ immunoscores. This applies both to gastro-
oesophageal adenocarcinoma tissue (which might therefore be assembled as a tissue 
microarray) and cell line blocks. 
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As stated above, background non-neoplastic cells can be used as internal controls for 
ISH studies. 
 
External 
It is recommended that any laboratory offering clinical HER2 testing of gastro-
oesophageal adenocarcinoma should participate in an appropriate external quality 
assurance (EQA) scheme. This is consistent with recommendation 2.7 of the CAP-
guidelines that laboratories should incorporate HER2 testing methods into the overall 
laboratory quality improvement program.[5] In the UK for example, UK NEQAS ICC and 
ISH run an annual EQA scheme for HER2 immunohistochemistry and ISH of gastro-
oesophageal adenocarcinomas. 
 
Audits 
The CAP-guidelines recommend that laboratories consider tracking their own statistics 
of HER2 results including inter-observer reproducibility between pathologists and 
histological subtypes.[5] These recommendations are endorsed. Previous studies have 
shown that 21 to 33% of intestinal-type carcinomas tested and 4 to 12% of diffuse-type 
carcinomas tested show HER2 positivity (defined as a 3+ immunoscore and/or HER2 
amplification).[22-25] These numbers are sufficiently consistent to formulate and 
recommend a specific audit standard that at least 20% of intestinal-type carcinomas 
tested and at least 4% of diffuse-type carcinomas tested show HER2 positivity as 
defined above.  
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Turnaround times 
Minimising the turnaround time of molecular testing for personalised medicine is 
clinically critical.[21] The CAP-guidelines recommend a benchmark of 90% of reports 
being available within 10 working days from the date of specimen acquisition.[5] In the 
NHS setting, immunohistochemistry is regarded as a relatively rapid test. Therefore, it is 
recommended that if only immunohistochemistry is required and is performed in house, 
>90% of cases are reported within 5 days of receipt or collection of the tissue block. If 
both immunohistochemistry and ISH are required and are performed in-house, then 
>90% of cases should be reported within 10 days of receipt or collection of the tissue. 
 
Like in the CAP-guidelines, it is acknowledged that some laboratories may out-source 
tissue for HER2 testing. The proposal of the CAP-guidelines that 90% of these 
specimens are sent to the testing laboratories within 3 working days of tissue 
processing,[5] is supported. 
  
FUTURE DIRECTIONS AND DEVELOPMENTS 
There is still controversy regarding the optimal model for IHC for the purposes of 
personalised medicine. Should it be every laboratory that can perform IHC, or just by 
selected laboratories that can treat these tests as bona fide molecular tests from a 
quality point of view?[26] At this point, a comparison with the breast HER2 IHC 
paradigm is pertinent. It is clear that mistakes had been made with HER2 testing of 
breast cancer, and there currently remain countries that do not allow Herceptin 
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treatment for this cancer unless the positive IHC result is confirmed by an ISH method 
run by a centralised laboratory. Some may therefore argue that, in Western countries 
where gastro-oesophageal adenocarcinoma is not as common as in Asia, HER2 testing 
should be consolidated in centres with a minimum number of tests per year, to ensure 
adequate quality assurance and control and accurate and consistent diagnostic 
interpretation. 
 
There continue to be attempts to fully automate the reading/scoring of HER2 
immunohistochemistry and ISH.  As yet, however, no particular computer based system 
has been fully validated for clinical use and therefore no such system can be 
recommended in this document.  Recommendation 2.8 of the CAP-guidelines states 
that there is insufficient evidence to recommend for or against genomic testing in 
gastro-oesophageal adenocarcinoma patients at the time of writing.[5] The tests 
discussed in these guidelines include multiplex ligation-dependent probe amplification 
and droplet digital PCR. The guidelines do state the possibility of genomic testing being 
useful for cases where standard IHC and/or ISH are not able to provide a conclusive 
finding, particularly when there is borderline amplification.[5] However, in the NHS 
setting, most if not all of these technologies, are not readily available to routine 
diagnostic laboratories.   
  
Finally, there is increasing interest in the use of next generation sequencing (NGS) to 
directly assess for HER2 gene amplification, therefore bypassing the need for HER2 
immunohistochemistry. This use of NGS has not yet been clinically validated. Such 
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validation will particularly need to consider the issue of tissue heterogeneity of HER2 
amplification and of HER2 amplification without increased protein expression. 
 
CONCLUSION 
The recommendations of the CAP-guidelines are welcomed and generally endorsed by 
this document. This document has, in addition, included guidance on tissue fixation and 
on specific audit standards. At the current time, the main recommendations for HER2 
testing of gastro-oesophageal adenocarcinoma, at least in the UK, are presented in 
Table 2. Future developments that will be monitored include the use of genomic tests 
for HER2 and especially next generation sequencing. 
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TABLE 2 
 
 
Cellular pathology laboratory number (if referred case, source cellular 
pathology laboratory number) 
 
Type of specimen tested (e.g. endoscopic biopsies, surgical resection 
specimen, peritoneal biopsy, liver biopsy, cytology cell block, etc.) 
 
Adenocarcinoma Lauren type (i.e. intestinal, diffuse, or mixed) 
 
If HER2 IHC performed: 
 
Antibody clone used 
 
HER2 immunoscore 
 
If HER2 ISH performed: 
 
Technique used (e.g. FISH, CISH, D-DISH) 
 
Probes used 
 
Average HER2 signal count 
 
Average CEP17 signal count 
 
HER2/CEP17 ratio 
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TABLE AND FIGURE LEGENDS 
Table 1 
Main recommendations for HER2 testing of gastro-oesophageal adenocarcinoma to 
guide trastuzumab therapy. 
 
Table 2 
Minimum dataset for reporting of HER2 IHC and/or ISH of gastro-oesophageal 
adenocarcinoma. 
 
Figure 
Examples of the Rüschoff/Hofmann grading system for HER2 immunohistochemistry of 
gastro-oesophageal adenocarcinoma: a) 3+; b) 2+; c) 1+ and d) 0 immunoscores.  
